A class action lawsuit has been filed against uniQure NV on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that the company misrepresented or failed to disclose that the design of its pivotal study for a Huntington's Disease drug was not fully approved by the FDA, and that additional studies might be required, potentially delaying its biologics license application. Investors claim they suffered damages when the true details became public. Those wishing to serve as lead plaintiff must act by April 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via Newsfile (Ref. ID: 202602161915NEWSFILECNPR____20260216_284062_1) on February 17, 2026, and is solely responsible for the information contained therein.